Back to top

Patrick Labonté

Looking for students or interns

Areas of expertise

Hepatitis C , Cellular and molecular characterization , Chronic viral hepatitis (HCV, HBV and HDV) , Protein study

  • Professor

Phone
450-687-5010

Fax
450-686-5501

Email
patrick.labonte@inrs.ca

Armand-Frappier Santé Biotechnologie Research Centre

531 blvd des Prairies
Laval, Quebec  H7V 1B7
CANADA

See the research centre

Research project for a master’s student in Virology and Immunology :Antiviral effects of nucleic acid polymers (NAP) in hepatitis B virus infections (HBV) (PDF) BiographyDr. Patrick Labonté obtained his B.Sc. in biochemistry from Université du Québec à Montréal and his master’s in microbiology and immunology from Institut Armand-Frappier in 1994. After his Ph.D., obtained from Université de Montréal in 2001, he joined the Infectious Disease Department of Wyeth Pharmaceutical, New York for a postdoctoral training. Dr. Labonté joined INRS-Institut Armand Frappier in 2003.

Publications

LE, Q. T., BLANCHET, M., SEIDAH, N. G. & LABONTÉ, P. (2015)
Plasma membrane CD81 complexes with PCSK9 and LDLR and its levels are reduced by PCSK9,
Journal of Biological Chemistry.

 

LE, Q. T., BLANCHET, M., SEIDAH, N. G. & LABONTÉ, P. (2015)
Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9,
Journal of Biological Chemistry, 290, 38, 23385-23400.

 

BLANCHET, M., SUREAU, C., GUEVIN, C., SEIDAH, N. G. & LABONTE, P. (2015)
SKI-1/S1P inhibitor PF-429242 impairs the onset of HCV infection,
Antiviral Research, 115, 94-104.

 

BLANCHET, M., SUREAU, C. & LABONTÉ, P. (2014)
Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle,
Antiviral Research, 106C, 111-115.

 

DELPEUT, S., RUDD, P. A., LABONTÉ, P. & VON MESSLING, V. (2012)
Membrane fusion-mediated autophagy induction enhances morbillivirus cell-to-cell spread
Journal of Virology , 86, 16, 8527-8535.

 

BLANCHET, M., SEIDAH, N. G. & LABONTÉ, P. (2012)
SKI-1/S1P inhibition: A promising surrogate to statins to block Hepatitis C virus replication
Antiviral Research , 95, 2, 159-166.

 

GUÉVIN, C., MANNA, D., BÉLANGER, C., KONAN, K. V., MAK, P. & LABONTÉ, P. (2010)
Autophagy protein ATG5 interacts transiently with the hepatitis C virus RNA polymerase (NS5B) early during infection
Virology , 405, 1, 1-7.

 

LABONTÉ, P., BEGLEY, S., GUÉVIN, C., ASSELIN, M. C., NASSOURY, N., MAYER, G., PRAT, A. & SEIDAH, N. G. (2009)
PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression
Hepatology (Baltimore, Md.) , 50, 1, 17-24.

 

GUÉVIN, C., LAMARRE, A. & LABONTÉ, P. (2009)
Novel HCV replication mouse model using human hepatocellular carcinoma xenografts
Antiviral Research , 84, 1, 14-22.

 

LABONTÉ, P. & SEIDAH, N. G. (2008)
Emerging viruses: Risk of pandemic
Expert Review of Anti-Infective Therapy , 6, 5, 581-583.

 

BENGUE, A. K. M., KOUACOU, M. J. L., EKAZA, E., SIRANSY-BOGUI, L., N’GOLO, D. C., LABONTÉ, P. & DOSSO, M. (2008)
Hepatitis C virus infection in Abidjan Cote d Ivoire: heterogeneity of genotypes
Scientific Research and Essays , 3, 4, 139-142.

 

AMIN, A., ZACCARDI, J., MULLEN, S., OLLAND, S., ORLOWSKI, M., FELD, B., LABONTÉ, P. & MAK, P. (2003)
Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase
Virology , 313, 1, 158-69.

 

LABONTÉ, P., MORIN, N., BOWLIN, T. & MOUNIR, S. (2002)
Basal replication of hepatitis C virus in nude mice harboring human tumor
Journal of Medical Virology , 66, 3, 312-9.

 

LABONTÉ, P., AXELROD, V., AGARWAL, A., AULABAUGH, A., AMIN, A. & MAK, P. (2002)
Modulation of hepatitis C virus RNA-dependent RNA polymerase activity by structure-based site-directed mutagenesis
Journal of Biological Chemistry , 277, 41, 38838-46.

 

MAK, P., PALANT, O., LABONTÉ, P. & PLOTCH, S. (2001)
Reconstitution of hepatitis C virus protease activities in yeast
FEBS Letters , 503, 1, 13-8.

 

LABONTÉ, P., KADHIM, S., BOWLIN, T. & MOUNIR, S. (2000)
Inhibition of tumor growth with doxorubicin in a new orthotopically implanted human hepatocellular carcinoma model
Hepatology Research , 18, 1, 72-85.

 

ALAOUI-ISMAILI, M. H., HAMEL, M., L’HEUREUX, L., NICOLAS, O., BILIMORIA, D., LABONTÉ, P., MOUNIR, S. & RANDO, R. F. (2000)
The hepatitis C virus NS5B RNA-dependent RNA polymerase activity and susceptibility to inhibitors is modulated by metal cations
Journal of Human Virology , 3, 6, 306-316.

 

LABONTÉ, P., MOUNIR, S. & TALBOT, P. J. (1995)
Sequence and expression of the ns2 protein gene of human coronavirus OC43
Journal of General Virology , 76, 2, 431-435.

 

MOUNIR, S., LABONTÉ, P. & TALBOT, P. J. (1993)
Characterization of the nonstructural and spike proteins of the human respiratory coronavirus OC43: comparison with bovine enteric coronavirus
Advances in Experimental Medicine and Biology , 342, 61-7.